Sie suchten nach: itp (Slowenisch - Englisch)

itp študijska populacija
itp study population

zdravila za zdravljenje itp
medicinal products for treatment of itp

trombembolični dogodki bolniki z itp
thromboembolic events itp patients

imunska trombocitopenična purpura (itp)
immune thrombocytopenic purpura (itp)

itp in rr nista neodvisni podjetji
itp and rr are not independent enterprises

zmanjšanje dovoljenih sočasnih zdravil za itp
reduction in permitted concurrent itp medical therapies

kolikšen odmerek zdravila revolade vzeti za itp
how much to take for itp

Študija z itp je bila opravljena pri 57 bolnikih.
the itp study was performed in 57 patients.

preglednica 1 prilagoditve odmerka eltrombopaga pri bolnikih z itp
table 1 dose adjustments of eltrombopag in itp patients

komisija je podrobno preverila povezavo med podjetjema itp in rr.
the commission has assessed in detail the relationship between itp and rr.

ob vključitvi v študijo so imeli itp diagnosticirano približno 2 leti.
patients had been diagnosed with itp for approximately 2 years at the time of study entry.

drugi možni neželeni učinki pri otrocih z itp zelo pogosti neželeni učinki
other possible side effects in children with itp very common side effects

na 100 kg suszonych słodkich ziemniaków, itp., lub kukurydzy.
na 100 kg suszonych słodkich ziemniaków, itp., lub kukurydzy.

druga študija je preučevala uporabo zdravila kiovig za imunomodulacijo pri 23 bolnikih z itp.
the second study looked at using kiovig for immunomodulation in 23 patients with itp.

v celotnem kliničnem programu itp so opažali obratno sorazmerje med pojavom krvavitev in številom trombocitov.
across the entire itp clinical programme an inverse relationship between bleeding events and platelet counts was observed.

v primeru prenehanja zdravljenja z romiplostimom je priporočljivo itp znova začeti zdraviti skladno z veljavnimi terapevtskimi smernicami.
it is recommended that, if treatment with romiplostim is discontinued, itp treatment be restarted according to current treatment guidelines.

možno tveganje, povezano s ponovnim zdravljenjem z zdravilom lemtrada po pojavu itp, ni znano.
the potential risk associated with retreatment with lemtrada following the occurrence of itp is unknown.

resne pojave itp so opazili pri približno 1 % bolnikov, zdravljenih v kontroliranih kliničnih preskušanjih pri ms.
serious events of itp have been observed in approximately 1% of patients treated in controlled clinical trials in ms.

primarna imunska trombocitopenija (itp), pri kateri je število trombocitov v krvi močno zmanjšano.
primary immune thrombocytopenia (itp), a condition where the number of platelets in the blood stream is greatly reduced.

hemoptiza lahko kaže tudi na itp (glejte zgoraj), zato je treba opraviti ustrezno diferencialno diagnostiko.
haemoptysis may also be indicative of itp (see above), and an appropriate differential diagnosis has to be undertaken.